Antitumor Molecular Mechanism of Trifluridine and Tipiracil Hydrochloride (TAS-102: TFTD)

Hiroyuki Kitao; Kazuaki Matsuoka; Makoto Iimori; Eriko Tokunaga; Hiroshi Saeki; Eiji Oki; Yuji Miyamoto; Hideo Baba; Yoshihiko Maehara

Antitumor Molecular Mechanism of Trifluridine and Tipiracil Hydrochloride (TAS-102: TFTD)

Hiroyuki Kitao, Kazuaki Matsuoka, Makoto Iimori, Eriko Tokunaga, Hiroshi Saeki, Eiji Oki, Yuji Miyamoto, Hideo Baba, Yoshihiko Maehara

Research output: Contribution to journal › Review article › peer-review

Abstract

Treatment options for patients with metastatic colorectal cancer (mCRC), who are refractory to standard chemotherapy, are limited. In a global multicenter randomized double-blind phase III study (RECOURSE study), TAS-102 (TFTD) administration significantly improved overall survival rate with favorable safety profile in mCRC patients refractory to standard chemotherapy (HR=0.68, p<0.001). TFTD was approved initially in Japan in March 2014 and is currently under review by health authorities in the United States and Europe. TFTD is expected to play an important role in salvage-line treatment for patients with mCRC. In this review, we present the history of its clinical development and the experimental data that elucidate the underlying molecular mechanism of action of TFTD and its key component, trifluridine.

Original language	English
Pages (from-to)	8-14
Number of pages	7
Journal	Gan to kagaku ryoho. Cancer & chemotherapy
Volume	43
Issue number	1
Publication status	Published - Jan 1 2016

All Science Journal Classification (ASJC) codes

Medicine(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{8638f81bb63f41988873eac40f0c8e5c,

title = "Antitumor Molecular Mechanism of Trifluridine and Tipiracil Hydrochloride (TAS-102: TFTD)",

abstract = "Treatment options for patients with metastatic colorectal cancer (mCRC), who are refractory to standard chemotherapy, are limited. In a global multicenter randomized double-blind phase III study (RECOURSE study), TAS-102 (TFTD) administration significantly improved overall survival rate with favorable safety profile in mCRC patients refractory to standard chemotherapy (HR=0.68, p<0.001). TFTD was approved initially in Japan in March 2014 and is currently under review by health authorities in the United States and Europe. TFTD is expected to play an important role in salvage-line treatment for patients with mCRC. In this review, we present the history of its clinical development and the experimental data that elucidate the underlying molecular mechanism of action of TFTD and its key component, trifluridine.",

author = "Hiroyuki Kitao and Kazuaki Matsuoka and Makoto Iimori and Eriko Tokunaga and Hiroshi Saeki and Eiji Oki and Yuji Miyamoto and Hideo Baba and Yoshihiko Maehara",

year = "2016",

month = jan,

day = "1",

language = "English",

volume = "43",

pages = "8--14",

journal = "Gan to kagaku ryoho. Cancer & chemotherapy",

issn = "0385-0684",

publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",

number = "1",

}

TY - JOUR

T1 - Antitumor Molecular Mechanism of Trifluridine and Tipiracil Hydrochloride (TAS-102: TFTD)

AU - Kitao, Hiroyuki

AU - Matsuoka, Kazuaki

AU - Iimori, Makoto

AU - Tokunaga, Eriko

AU - Saeki, Hiroshi

AU - Oki, Eiji

AU - Miyamoto, Yuji

AU - Baba, Hideo

AU - Maehara, Yoshihiko

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Treatment options for patients with metastatic colorectal cancer (mCRC), who are refractory to standard chemotherapy, are limited. In a global multicenter randomized double-blind phase III study (RECOURSE study), TAS-102 (TFTD) administration significantly improved overall survival rate with favorable safety profile in mCRC patients refractory to standard chemotherapy (HR=0.68, p<0.001). TFTD was approved initially in Japan in March 2014 and is currently under review by health authorities in the United States and Europe. TFTD is expected to play an important role in salvage-line treatment for patients with mCRC. In this review, we present the history of its clinical development and the experimental data that elucidate the underlying molecular mechanism of action of TFTD and its key component, trifluridine.

AB - Treatment options for patients with metastatic colorectal cancer (mCRC), who are refractory to standard chemotherapy, are limited. In a global multicenter randomized double-blind phase III study (RECOURSE study), TAS-102 (TFTD) administration significantly improved overall survival rate with favorable safety profile in mCRC patients refractory to standard chemotherapy (HR=0.68, p<0.001). TFTD was approved initially in Japan in March 2014 and is currently under review by health authorities in the United States and Europe. TFTD is expected to play an important role in salvage-line treatment for patients with mCRC. In this review, we present the history of its clinical development and the experimental data that elucidate the underlying molecular mechanism of action of TFTD and its key component, trifluridine.

UR - http://www.scopus.com/inward/record.url?scp=84965093493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965093493&partnerID=8YFLogxK

M3 - Review article

C2 - 26809521

AN - SCOPUS:84965093493

SN - 0385-0684

VL - 43

SP - 8

EP - 14

JO - Gan to kagaku ryoho. Cancer & chemotherapy

JF - Gan to kagaku ryoho. Cancer & chemotherapy

IS - 1

ER -

Antitumor Molecular Mechanism of Trifluridine and Tipiracil Hydrochloride (TAS-102: TFTD)

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Other files and links

Fingerprint

Cite this